Streetbeat News

AEMD

Aethlon Medical, Inc.

https://www.aethlonmedical.com

Industry

Medical - Devices

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

Open

0.39

Mkt cap

5.6M

Volume

271K

High

0.42

P/E Ratio

-0.14

52-wk high

2.35

Low

0.38

Div yield

N/A

52-wk low

0.24

Biotech and medical tech stocks are advancing in cancer treatment as global cancer rates rise. Aethlon Medical, Inc. (NASDAQ: AEMD) is highlighted for its focus on developing products for cancer and infectious diseases. The solid tumors market was valued at $170.3 billion in 2023.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

Aethlon Medical, Inc. (AEMD) held its Q2 2025 earnings call, providing updates on its financial performance and corporate activities. Key participants included Michael Miller, James Frakes, and Steven LaRosa.

Portfolio Pulse from

November 14, 2024 | 1:15 am

Aethlon Medical reported its fiscal second quarter results and announced the enrollment of the first two patients in its Hemopurifier® study for solid tumors. Two Australian sites are now open for patient enrollment. A conference call is scheduled for today.

Portfolio Pulse from

November 13, 2024 | 9:30 pm

Aethlon Medical, Inc. (NASDAQ: AEMD) has begun enrolling patients in trials for its innovative medical technology aimed at treating cancer and infectious diseases. This marks a significant step forward in the medical technology sector, which is expected to see substantial revenue growth.

Portfolio Pulse from

November 12, 2024 | 1:15 pm

Aethlon Medical, Inc. (Nasdaq: AEMD) will release its fiscal second quarter financial results on November 13, 2024. The company focuses on developing treatments for cancer and infectious diseases.

Portfolio Pulse from

November 06, 2024 | 1:15 pm

The World Health Organization (WHO) has expanded its emergency use list for Mpox diagnostics by adding Cepheid's Xpert Mpox PCR test and Roche's Cobas MPXV assay as PCR-based gold standard options.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 1:25 pm

A new mpox variant, clade 1b, has been detected in Germany, as reported by the Robert Koch Institute. This development could have implications for companies involved in vaccine development and public health response.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 3:08 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. Notable gainers include Carmell (CTCX), Clearside Biomedical (CLSD), and Kezar Life Sciences (KZR), while Nexalin Technology (NXL) and Tivic Health Systems (TIVC) were among the losers.

Portfolio Pulse from Benzinga Insights

October 09, 2024 | 12:07 pm

Los Angeles County reports a doubling of mpox cases, urging vaccinations for high-risk groups. The JYNNEOS vaccine is available at pharmacies and public health clinics. Health officials recommend safe sex practices and testing for symptoms.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 3:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.